These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 31489324)
61. Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Sinn DH; Yi J; Choi MS; Choi D; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Yoo BC Hepatol Int; 2013 Oct; 7(4):1010-8. PubMed ID: 26202030 [TBL] [Abstract][Full Text] [Related]
62. Clinicopathological characteristics of hepatocellular carcinoma bearing Mallory bodies: an autopsy study. Hoso M; Nakanuma Y Liver; 1990 Oct; 10(5):264-8. PubMed ID: 1701511 [TBL] [Abstract][Full Text] [Related]
63. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Fetzer DT; Rodgers SK; Harris AC; Kono Y; Wasnik AP; Kamaya A; Sirlin C Radiol Clin North Am; 2017 Nov; 55(6):1197-1209. PubMed ID: 28991560 [TBL] [Abstract][Full Text] [Related]
64. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Lee NP; Cheung ST; Poon RT; Fan ST; Luk JM Biomark Med; 2007 Aug; 1(2):273-84. PubMed ID: 20477402 [TBL] [Abstract][Full Text] [Related]
65. Surveillance for hepatocellular carcinoma: how can we do better? Hassett M; Yopp AC; Singal AG Am J Med Sci; 2013 Oct; 346(4):308-13. PubMed ID: 23426089 [TBL] [Abstract][Full Text] [Related]
66. Surveillance for hepatocellular carcinoma. Sherman M Semin Oncol; 2001 Oct; 28(5):450-9. PubMed ID: 11685738 [TBL] [Abstract][Full Text] [Related]
67. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Stroffolini T; Trevisani F; Pinzello G; Brunello F; Tommasini MA; Iavarone M; Di Marco V; Farinati F; Del Poggio P; Borzio F; Borzio M; Caturelli E; Di Nolfo MA; Frigerio M; Brancaccio G; Gaeta GB Dig Liver Dis; 2011 Nov; 43(11):875-80. PubMed ID: 21684821 [TBL] [Abstract][Full Text] [Related]
68. Increasing burden of advanced hepatocellular carcinoma in New Zealand-the need for better surveillance. Schauer C; Mules T; Rijnsoever MV; Gane E N Z Med J; 2020 May; 133(1515):25-34. PubMed ID: 32438374 [TBL] [Abstract][Full Text] [Related]
69. A propensity score-matched case-control comparative study of laparoscopic and open liver resection for hepatocellular carcinoma. Wang C; Luo W; Fu Z; Sun M; Si H; Guo D J BUON; 2017; 22(4):936-941. PubMed ID: 28952210 [TBL] [Abstract][Full Text] [Related]
70. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. Arslanoglu A; Seyal AR; Sodagari F; Sahin A; Miller FH; Salem R; Yaghmai V AJR Am J Roentgenol; 2016 Nov; 207(5):W88-W98. PubMed ID: 27490855 [TBL] [Abstract][Full Text] [Related]
71. Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis. Tabibian JH; Landaverde C; Winn J; Geller SA; Nissen NN Ann Hepatol; 2009; 8(1):64-7. PubMed ID: 19221537 [TBL] [Abstract][Full Text] [Related]
72. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Dyer Z; Peltekian K; van Zanten SV Aliment Pharmacol Ther; 2005 Jul; 22(1):17-22. PubMed ID: 15963075 [TBL] [Abstract][Full Text] [Related]
73. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Sakisaka S; Watanabe M; Tateishi H; Harada M; Shakado S; Mimura Y; Gondo K; Yoshitake M; Noguchi K; Hino T Hepatology; 1993 Dec; 18(6):1357-62. PubMed ID: 7694895 [TBL] [Abstract][Full Text] [Related]
74. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Giannini E; Arzani L; Borro P; Botta F; Fasoli A; Risso D; Celle G; Testa R Hepatogastroenterology; 2000; 47(35):1395-8. PubMed ID: 11100360 [TBL] [Abstract][Full Text] [Related]
75. Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis. Tao P; Gao L; Li H; Wang B; Li X; Zhang Y; Chen H Medicine (Baltimore); 2020 Dec; 99(52):e23841. PubMed ID: 33350772 [TBL] [Abstract][Full Text] [Related]
76. Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. Zhang L; Zhao H Hepatobiliary Surg Nutr; 2020 Jun; 9(3):348-349. PubMed ID: 32509826 [No Abstract] [Full Text] [Related]
77. Hepatocellular carcinoma surveillance: an open question. Biselli M; Garuti F; Neri A Hepatobiliary Surg Nutr; 2019 Aug; 8(4):431-432. PubMed ID: 31489324 [No Abstract] [Full Text] [Related]
78. Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. van Meer S; de Man RA; Coenraad MJ; Sprengers D; van Nieuwkerk KM; Klümpen HJ; Jansen PL; IJzermans JN; van Oijen MG; Siersema PD; van Erpecum KJ J Hepatol; 2015 Nov; 63(5):1156-63. PubMed ID: 26100498 [TBL] [Abstract][Full Text] [Related]